Le Lézard19m
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a ...